#Cipla today said the company doesn't have a definitive agreement on commercial supplies of the Moderna vaccine. Viswanath Pilla reports here 👇
https://www.moneycontrol.com/news/business/companies/cipla-says-no-definitive-pact-on-commercial-supplies-of-moderna-vaccine-7104731.html?utm_source=telegram&utm_medium=soc
https://www.moneycontrol.com/news/business/companies/cipla-says-no-definitive-pact-on-commercial-supplies-of-moderna-vaccine-7104731.html?utm_source=telegram&utm_medium=soc
Moneycontrol
Cipla Says Doesn't Have Definitive Pact On Commercial Supplies Of Moderna Vaccine
Cipla said it is supporting Moderna with the regulatory approval and importation of vaccines to be donated to India. The government of India has issued a registration certificate and a permission to import the COVID-19 Vaccine Moderna for restricted use in…
#Cipla today entered into a pact with Bengaluru-based Kemwell Biopharma CDMO, to develop, manufacture and commercialise biosimilars for global markets.
https://www.moneycontrol.com/news/business/companies/cipla-partners-kemwell-to-foray-into-respiratory-biosimilars-space-7388871.html?utm_source=telegram&utm_medium=social
https://www.moneycontrol.com/news/business/companies/cipla-partners-kemwell-to-foray-into-respiratory-biosimilars-space-7388871.html?utm_source=telegram&utm_medium=social
Moneycontrol
Cipla Partners Kemwell To Foray Into Respiratory Biosimilars Space
Cipla’s respiratory drug prowess combined with Kemwell’s expertise in biologics will accelerate bringing these essential products to market.
#EarningsWithMC: As #Cipla gets ready to declare its numbers for the second quarter today, take a look at what the experts expect 👇
https://www.moneycontrol.com/news/business/earnings/cipla-q2-results-preview-topline-likely-to-increase-4-bottomline-6-say-experts-7623571.html?utm_source=telegram&utm_medium=social
https://www.moneycontrol.com/news/business/earnings/cipla-q2-results-preview-topline-likely-to-increase-4-bottomline-6-say-experts-7623571.html?utm_source=telegram&utm_medium=social
Moneycontrol
Cipla Q2 Results Preview: Topline Likely To Increase 4%, Bottomline 6%, Say Experts
Investors would look at the outlook for limited competition pipeline in the US, decision on Avenue Therapeutics and update on inhaler products for the US
#MarketsWithMC: #Cipla share price rose over 2% intraday to Rs 883.90 after its Lanreotide injection got the green light from the USFDA.
Read at
https://www.moneycontrol.com/news/business/stocks/cipla-shares-gain-2-on-final-fda-approval-for-lanreotide-injection-7843551.html?utm_source=telegram&utm_medium=social
Read at
https://www.moneycontrol.com/news/business/stocks/cipla-shares-gain-2-on-final-fda-approval-for-lanreotide-injection-7843551.html?utm_source=telegram&utm_medium=social
Moneycontrol
Cipla Shares Gain 2% On Final FDA Approval For Lanreotide Injection
Foreign research firm Nomura has kept a 'buy' call on the stock with a target at Rs 1,051 per share
#MarketsWithMC | #Cipla reported a consolidated PAT of Rs 362 crore for the March quarter, a decline of 12% from a year ago.
Here is what brokerages have to say about the stock and the company after earnings 👇
https://www.moneycontrol.com/news/business/stocks/as-cipla-falls-after-earnings-should-you-buy-or-sell-stock-8485681.html?utm_source=telegram&utm_medium=social
Here is what brokerages have to say about the stock and the company after earnings 👇
https://www.moneycontrol.com/news/business/stocks/as-cipla-falls-after-earnings-should-you-buy-or-sell-stock-8485681.html?utm_source=telegram&utm_medium=social
Moneycontrol
As Cipla falls after earnings; should you buy or sell stock?
Cipla on May 10 reported a consolidated profit after tax (PAT) of Rs 362 crore for the quarter ended March, a decline of 12 percent from a year ago. The company had registered a PAT of Rs 729 crore in the previous quarter.
#MCProPanorama: The auto sector is facing a series of roadblocks – from chip shortage to soft demand to sticky fuel prices.
Can it manage to keep earnings downgrades at bay? Also on, #AsianPaints, #Cipla, and more 👇
https://www.moneycontrol.com/news/opinion/moneycontrol-pro%e2%80%8b-panorama-auto-wreck-8497241.html?utm_source=telegram&utm_medium=social
Can it manage to keep earnings downgrades at bay? Also on, #AsianPaints, #Cipla, and more 👇
https://www.moneycontrol.com/news/opinion/moneycontrol-pro%e2%80%8b-panorama-auto-wreck-8497241.html?utm_source=telegram&utm_medium=social
Moneycontrol
Moneycontrol Pro Panorama | Auto wreck
In today’s edition of Moneycontrol Pro Panorama: Bond yields flashing red, Sri Lankan crisis decoded, Jinping eyes third term, Start-Up Street and more
#TradeSetup for August 17⚡️#SBI, #Cipla, #BharatGears & more.
Check out this curated list of buzzing #stocks and why they are in the news 📹👇
https://www.youtube.com/watch?v=Gi7CblBc1LM
Check out this curated list of buzzing #stocks and why they are in the news 📹👇
https://www.youtube.com/watch?v=Gi7CblBc1LM
#TradeSetup for September 1st ⚡️ #TataMotors, #Cipla, #SunteckRealty and more.
Check out this curated list of buzzing stocks and why they are in the news 📹👇
https://bit.ly/3TsFDvf
Check out this curated list of buzzing stocks and why they are in the news 📹👇
https://bit.ly/3TsFDvf
#NewsAlert 🚨Income Tax department investigating Cipla for potential tax violations: Sources to CNBC-TV18
Cipla says no claim or demand made by Income Tax Dept
#Cipla #IncomeTax #Tax
Cipla says no claim or demand made by Income Tax Dept
#Cipla #IncomeTax #Tax